Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis.
Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies.
Validation survey of the impact of urinary incontinence (IIQ-7) and inventory of distress urogenital (UDI-6) - the short scales - in patients with multiple sclerosis.
Genomic imprinting: A missing piece of the Multiple Sclerosis puzzle?
Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex(R)) in people with multiple sclerosis: a new approach.
Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.
Association of sex hormones and glucose metabolism with the severity of multiple sclerosis.
FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs
Silencing of Abcc8 or inhibition of newly upregulated Sur1-Trpm4 reduce inflammation and disease progression in experimental autoimmune encephalomyelitis.
Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study.
Multiple sclerosis in Syria.
Reducing survey burden: feasibility and validity of PROMIS measures in multiple sclerosis.
Changes in Gross Grasp Strength and Fine Motor Skills in Adolescents with Pediatric Multiple Sclerosis.
Exosomes in neurologic and psychiatric disorders.
Brain atrophy at onset and physical disability in multiple sclerosis.
Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system.
New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis.
Incidence and distribution of extravascular compression of extracranial venous pathway in patients with chronic cerebrospinal venous insufficiency and multiple sclerosis.
Myelination: Do Astrocytes Play a Role?
The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination.
Central Veins in Brain Lesions Visualized With High-Field Magnetic Resonance Imaging: A Pathologically Specific Diagnostic Biomarker for Inflammatory Demyelination in the Brain.
Peripheral elevation of TNF-α leads to early synaptic abnormalities in the mouse somatosensory cortex in experimental autoimmune encephalomyelitis.
Second generation S1P pathway modulators: Research strategies and clinical developments.
A history of multiple sclerosis investigations in Canada between 1850 and 1950.
RORs in Autoimmune Disease.
Pages
« first
‹ previous
…
344
345
346
347
348
349
350
351
352
…
next ›
last »